Small for gestational age (SGA) babies have always been one of the silent red flags in obstetrics. When a fetus drops below the 10th centile for age for gestational age, we worry because SGA is not just about being small. It is about the possibility of an underperforming placenta, fetal growth restriction, and a frighteningly higher risk of stillbirth. Despite detailed risk assessment, doppler surveillance, aspirin prophylaxis, and structured pathways, nearly three-quarters of SGA babies still go undetected before birth.
Why does this gap exist? Because our current tools pick up consequences of placental dysfunction after they have already begun. What we desperately need is a screening tool that can detect risk before growth begins to fall.
This is where the new innovation steps in- microRNA Plasma Markers. Placental miRNAs, released into the maternal blood, acts like early biological “whispers” signalling dysfunction long before ultrasound can. A panel of just 7 miRNAs can identify women at risk of SGA, using the maternal blood sample already collected during the routine early pregnancy screening, that is at 13 weeks.
A low-cost, non-invasive test that predicts SGA early. This is not just technology - it is a chance to save babies, focus resources, and change the entire trajectory of SGA management in the modern obstetrics. Its practical use is still under consideration and evaluation. Hopefully, this will pass as a screening tool for SGA and give a new direction for detection & management of these cases.
The introduction of microRNA plasma markers is a remarkable advancement in obstetric screening. For decades, SGA detection has struggled because traditional tools only recognise placental dysfunction after growth has already fallen behind. The idea that a simple maternal blood sample at 13 weeks can detect placental stress through a 7-miRNA panel is truly transformative. Early prediction means earlier intervention, closer surveillance, and potentially preventing stillbirths that often occur silently. While the technology is still under evaluation, its promise lies in shifting SGA management from reactive to proactive. If validated, this could reshape prenatal care and save countless vulnerable babies.
We need such screening tools to save many lives. A strong diagnostic or screening tool is essential to detect SGA at the same time needs to be affordable for all economic classes.
MicroRNA plasma markers offer a promising early, non-invasive test to detect risk of SGA babies at 13 weeks, potentially improving detection and outcomes in prenatal care.